Rani Therapeutics Holdings Inc. has announced an amendment to its existing Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. Effective as of September 30, 2025, Avenue has agreed to convert $6.0 million of outstanding loans into 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof) as part of a private placement. Additionally, Avenue will receive warrants to purchase up to 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof) on the same terms as other purchasers. The amendment is part of Rani Therapeutics' ongoing efforts to strengthen its financial position.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-241963), on October 17, 2025, and is solely responsible for the information contained therein.